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Alexandra Rümmele-Waibel4, Laureane Mittaz-Crettol5, Julia Wanschitz6, Luisa Bonafé5, 
Kathrin Maurer7, Andrea Superti-Furga8 & Sabine Scholl-Bürgi1
Multicentric osteolysis, nodulosis and arthropathy (MONA) spectrum disorder is a rare inherited 
progressive skeletal disorder caused by mutations in the matrix metalloproteinase 2 (MMP2) gene. 
Treatment options are limited. Herein we present successful bisphosphonate therapy in three affected 
patients. Patients were treated with bisphosphonates (either pamidronate or zoledronate) for 
different time periods. The following outcome variables were assessed: skeletal pain, range of motion, 
bone densitometry, internal medical problems as well as neurocognitive function. Skeletal pain was 
dramatically reduced in all patients soon after initiation of therapy and bone mineral density increased. 
Range of motion did not significantly improve. One patient is still able to walk with aids at the age of 14 
years. Neurocognitive development was normal in all patients. Bisphosphonate therapy was effective 
especially in controlling skeletal pain in MONA spectrum disorder. Early initiation of treatment seems to 
be particularly important in order to achieve the best possible outcome.
Multicentric osteolysis, nodulosis and arthropathy (MONA, MIM #259600) spectrum disorder syndrome is a rare 
genetic chronic skeletal disorder characterized by multiple peripheral osteolysis, wide metacarpals, osteoporosis, 
progressive joint contractures, short stature, subcutaneous nodules as well as a coarse face, skin lesions/hirsutism 
and ocular and cardiac manifestations. Intelligence is normal in the affected patients1–11. The diagnosis is based on 
the typical clinical features together with normal laboratory findings, which allow this disease to be distinguished 
from other syndromes, including fibrotic, rheumatic and lysosomal diseases. MONA spectrum disorder is caused 
by mutations in the MMP2 gene (16q12.2) as reported by Martignetti et al. in ref. 7. MONA spectrum disorder is 
considered to be a continuous clinical spectrum involving also Torg, nodulosis, arthropathy and osteolysis (NAO) 
and Winchester syndrome
The pathogenesis of the disorder remains unclear12. To date 43 cases from 26 families with 20 different 
mutations in the MMP2 gene have been reported13. The enzyme MMP2 belongs to a family of zinc-dependent 
matrix-degrading enzymes involved in the regulation of angiogenesis14,15, normal collagen turnover16 and tumor 
cell invasiveness17. MMP2 is a major degrader of gelatin and type IV collagen, the major structural component 
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of the basement membrane, as well as elastin, laminin, fibronectin, aggrecan and fibrillin18. The actual MMP2 
cytogenetic band is 16q12.2.
So far therapy of patients with MONA spectrum disorder has been mainly limited to symptomatic analgesic 
therapy as well as physical and occupational therapy12. Phadke et al.19 were the first to report beneficial effects of 
bisphosphonate therapy in MONA spectrum disorder.
In this study we retrospectively analyze the clinical course of three siblings with MONA spectrum disorder 
over a ten-year period, who were also treated with intravenous bisphosphonates.
Results
Characteristics of the patients. The three reported patients are the children of healthy Turkish parents, 
who were born after uneventful pregnancies. The parents reported not to be related to each other. A fourth male 
child of the family is healthy.
Patient 1 is the oldest of the reported siblings. She is currently 14 years old and developed painful swelling and 
contractures of the small hand and foot joints with multiple low-impact fractures, especially of the metatarsal 
bones, from the age of 3 years on. A coarse face and hypertrichosis but no subcutaneous nodules were present 
(Fig. 1). Patient 1 was diagnosed with MONA spectrum disorder only 4 years after the symptoms had started to 
appear, i.e. when she was 7 years old. Prior to MONA spectrum disorder a 3-methyl-crotonyl-CoA-carboxylase 
deficiency (3-MCC deficiency) had already been diagnosed in this patient. This is a rare autosomal recessive dis-
order of L-leucine metabolism20 causing neurological symptoms and acute metabolic decompensation triggered 
by common infections. None of these symptoms had ever been noted in patient 1. However based on published 
data showing that only less than 10% of the affected individuals ever develop minor symptoms and only less then 
1% to 2% might be at risk for severe adverse outcome21. None of the patients with 3-MCC deficiency is reported 
to have a skeletal phenotype. Still, it was briefly thought to be the cause of the skeletal symptoms in Patient 1. For 
this reason oral L-carnitine supplementation, the recommended therapy in case of 3-MCC deficiency, was started. 
Dietary L-leucine restriction was not initiated as the efficacy of this approach for 3-MCC deficiency is unproven22.
As Patient 1 also showed signs of myopathy and neuropathy with reduced muscle strength and deep tendon 
reflexes, a muscle-tendon biopsy (musculus gastrognemicus/Achilles tendon) was performed at the age of 6 years. 
It demonstrated mild muscle fibre atrophy (Fig. 2a) and an accumulation of mononuclear inflammatory cells, 
especially around vessels within the fat connective tissue at the muscle-tendon junction (Fig. 2b). The enzyme 
histochemical stain for nicotinamide adenine dinucleotide-tetrazolium reductase demonstrated regular enzyme 
activity, but slight atrophy of type II fibres (Fig. 2c). Thus, additionally to oral L-carnitine supplementation, 
immunosuppressive therapy with azathioprine (2 mg/kg) was commenced. Both L-carnitine supplementation 
and azathioprine therapy were discontinued after the diagnosis of MONA spectrum disorder had been estab-
lished when the patient was 7 years old.
Patient 2, currently 9 years old, and Patient 3, currently 7 years old, had a similar history. Both younger siblings 
experienced first symptoms at the age of 2 years. Clinical examination revealed decreased range of motion in the 
fingers, wrists, ankles and toes with contractures of the interphalangeal joints. In Patient 2 we additionally diag-
nosed an iris coloboma and a ventricular septal defect, which were treated conservatively. Patient 3 had a secun-
dum atrial septal defect and a vesicoureteral reflux II°–III°, without any episodes of recurrent urinary infections. 
Figure 1. Patient 1 at the age of 4 years, when first symptoms of MONA spectrum disorder developed. She 
shows mild coarsening of the face (a). At the age of 12 years severe flexion contractures were present in both her 
feet (b) and hand joints (c).
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The diagnosis of MONA spectrum disorder was genetically confirmed when the patients were 7 years (Patient 2) 
and 5 years (Patient 3) old respectively.
All three patients received concomitant physical and occupational therapy from when first symptoms of 
MONA spectrum disorder appeared. Before initiation of bisphosphonate therapy all three patients needed regular 
analgesic therapy with non-steroidal anti-inflammatory drugs three times a day.
All three patients were found to carry the same homozygous mutation c.[1699C > T] in exon 11 of the MMP2 
gene. This mutation had not been reported previously but is very likely to be pathogenic as it leads to the intro-
duction of a premature stop codon, p.[Arg567Ter], and early truncation of the MMP2 protein. The same mutation 
was then identified in heterozygosity in the healthy brother as well as in the parents.
Bisphosphonate therapy. In Patient 1 bisphosphonate therapy was started already 3 years before the diag-
nosis of MONA spectrum disorder was established, i.e. when Patient 1 was 4 years old. She received intravenous 
pamidronate (1 mg/kg/d on two consecutive days every 3 months) for the treatment of osteolysis and osteopenia 
for eight consecutive years. Then, for convenience of the patient and because reported to be equally effective, the 
therapy was switched to intravenous zoledronate (0.05 mg/kg/d in a single dose), which in contrast to pamidro-
nate has to be given not every 3 month but only every 6 month.
Patients 2 and 3 were started to treat with zoledronate after the diagnosis of MONA spectrum disorder had 
been genetically confirmed, which was at the age of 7 and 5 years respectively, i.e. 5 and 3 years after first clinical 
symptoms had appeared.
Disease progression and therapeutic success. All three patients had normal developmental milestones, 
were of normal intelligence and frequented regular school. During follow-up no particular internal medical prob-
lems were noted. Patient 1 transiently showed mild signs of myopathy and neuropathy, which resolved spontane-
ously. The other siblings did not show any neurological symptoms.
The main sequealae for the patients were the evolving orthopaedic problems related to MONA spectrum 
disorder. All three patients showed short stature. In Patient 1 joint destruction progressed towards proximal to 
involve the wrists, elbows and knees, resulting in flexion contractures. Orthopaedic surgical treatment of a radial 
head dislocation was necessary. Details on this orthopaedic procedure have already been reported before in the 
study of AlKaissi et al., were Patient 1 corresponds to Patient III23. Patient 2 and Patient 3 even had a more severe 
evolution in terms of joint destruction and flexion contractures as documented by radiographs of hands and feet, 
which demonstrate general osteopenia, multiple osteolysis, widening of the phalanges and irregular epiphyses 
(Figs 3 and 4) but no low impact fractures. Still, all three patients depended on regular analgesic therapy with 
non-steroidal anti-inflammatory drugs three times a day. Physical and occupational therapy were only slightly 
able to ameliorate skeletal pain in the patients.
Bisphosphonate therapy significantly reduced skeletal pain in our patients. Frequency of need for analgesic 
therapy diminished to a single therapeutic dose 3–4 times a month. Bone densitometry demonstrated that bis-
phosphonate therapy led to a steady increase in bone mineral content both in the axial and in the appendicular 
skeleton in all three patients. Bone mineral content was below the 3rd percentile at all measured times. It showed 
a steady increase, with a curve similar to that for age, sex- and ethnicity-matched healthy controls, although the 
discrepancy appeared to slightly grow with age24. Figure 5 exemplarily demonstrates data for Patient 1, as she has 
the longest observation period (8 years so far) (Fig. 5a–c). No further low-impact fractures occurred after starting 
bisphosphonate therapy. Patient 1 showed the best outcome. Although the nature of the disease is progressive, she 
is still able to walk with aids and use her hand for writing.
Patients 2 and 3 have a more severe disease course. Although they are pain-free, they are severely impaired in 
their daily life. This impairment primarily results from impaired movement of wrist and finger joints as well as 
from the fact that both siblings are wheelchair bound.
No adverse effects of bisphosphonate treatment, such as severe hypocalcaemia or nephrocalcinosis, were 
noted during this treatment period of ten years.
Figure 2. Hematoxylin and eosin stain of the muscle-tendon biopsy of patient 1 at the age of 4.5 years shows a 
mildly increased fiber size variability (a). Immuno-histochemistry using antibodies against leucocyte common 
antigen (LCA) revealed an accumulation of mononuclear inflammatory cells especially perivascularly at the 
muscle-tendon junction (b). NADH-TR stain indicates a regular enzyme activity, but the weakly stained type II 
fibers are smaller than the more intensely stained type I fibers (c); original magnifications x20.
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Discussion
In this study we report successful bisphosphonate therapy in three siblings affected from MONA spectrum 
disorder.
MONA spectrum disorder is characterized by short stature, severe joint contractures, peripheral corneal 
opacities, coarse face, osteolysis of carpal and tarsal bones as well as generalized osteopenia25. Characteristics of 
patients reported in the literature are summarized in Table 1 (Table 1). Only patients with a genetically confirmed 
diagnosis were included in the table. The underlying cause of MONA spectrum disorder is a mutation in the gene 
encoding MMP24,7.
The three sisters reported here presented with typical clinical findings and were diagnosed as having MONA 
spectrum disorder based on the molecular analysis revealing a novel stop mutation in the MMP2 gene. From the 
genetic findings we strongly suspect that the patients’ parents are consanguineous.
Patient 1 was identified to additionally have a 3-MCC deficiency. This was already reported in the study of 
AlKaissi et al., were Patient 1 corresponds to Patient III23. It is the first time that an inborn disorder of metabo-
lism was observed in a patient with MONA spectrum disorder (Table 1). However, the association is likely to be 
fortuitous.
Patients 2 and 3 both show additional cardiac manifestations, i.e. a VSD and an ASD. This emphasizes a possi-
ble role of MMP2 in the pathophysiology of cardiac pathologies suggested by experimental studies26–28, especially 
as cardiac manifestations have already been reported in several patients with MONA spectrum disorder5,9.
Little information on the treatment of MONA spectrum disorder is given in the literature. Controversial data 
exist regarding immunosuppressive treatment. Al-Mayouf et al. reported an inhibitory effect of methotrexate 
combined with D-penicillamines on progression of joint contractures29. Tuysuz et al. noted an improvement in 
contractures in only one patient under prednisolone therapy, but not in his similarly affected cousin30.
In our patients we detected significant clinical improvement under bisphosphonate therapy. Bisphosphonates 
decrease osteoclastic activity, thereby favouring bone formation31. In paediatric patients they are used to treat 
conditions like osteoporosis and osteogenesis imperfecta. These agents have been reported to have analgesic 
effects, improve range of movement, function and bone mineral content32. With bisphosphonate therapy we were 
able to reduce the need for non-steroidal analgesics from three times a day to 3–4 times a month in our patient, 
which dramatically improved their quality of life. Bisphosphonate therapy was not able to significantly improve 
range of motion. Still, one of the reported patients is able to walk with aids at the age of 14 years. This has been 
reported only in three other adult patients by Azzollini et al.1 and Jeong et al.6, which again underlies the broad 
Figure 3. Dorsopalmar radiographs of the left hand demonstrate severe general osteopenia, progressive 
destruction of carpal bones and joints, multiple osteolyses, widening of phalanges and metacarpals with 
thinning of cortical bone and irregular epiphyses. Pronounced sklerotic metaphyseal lines most evident at the 
radial and ulnar bone are due to bisphosphonate therapy.
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inter- and intrafamilial variability of MONA spectrum disorder. We are also aware that our study suffers from the 
limitation of a retrospective design.
Bisphosphonate therapy also led to an increase in bone mineral content in the axial and the appendicular skel-
eton in all three patients. Bone mineral content in the patients was always below the 3rd percentile, but increase 
rate was similar to that of age-, sex- and ethnicity-matched healthy controls (Fig. 5), although the discrepancy 
with these controls appeared to slightly grow with age regardless of the site of measurement. The reason is unclear. 
We hypothesize that it might be related to a decreasing level of physical activity of the patients as the disease 
progresses. It might also be related to the changing hormonal regulation during puberty, which eventually has 
a negative impact on bone mineral density in patients with MONA spectrum disorders. However this is highly 
speculative and further studies will be needed to clarify this point.
After initiation of bisphosphonate treatment no further low-impact fractures occurred in the herein reported 
patients. Effects were similar for both agents used (pamidronate and zoledronate). We do not attribute the more 
favourable clinical outcome of patient 1 to the fact that she was initially treated with pamidornate while treatment 
in the siblings was started with zoledronate. We hypothesize that the more benign course might be related to early 
initiation of bisphosphonate therapy in this patient (one year after appearance of first clinical symptoms). In con-
trast in Patient 2 and 3 bisphosphonate therapy was only started 5 and 3 years respectively after clinical symptoms 
had appeared. Furthermore Patient 1 developed first symptoms of MONA spectrum disorder at the age of 4 years 
whereas Patient 2 and 3 showed first symptoms already when they were 2 years old. This reflects intrafamilial 
variability in the disease course with siblings 2 and 3 being more severely affected. Also we do not suspect that the 
favourable course of Patient 1 was due to the initial combination of immunosuppressive therapy with azathioprin 
Figure 4. Dorsoplantar radiographs of the feet show general osteopenia, progressive joint destruction 
and osteolyses most pronounced at the tarsal bones. Patients 2 and 3 have more severe findings compared to 
patient 1.
Figure 5. Bisphosphonate therapy increased overall bone mineral content (a), as well as bone mineral content 
in the axial (b) and appendicular skeleton (c). Bone mineral content was below the 3rd percentile at all 
measured time points but increase was steady and similar to age, sex and ethnicity matched healthy controls24 *.  
Data are given exemplarily for patient 1 including therapeutic interventions (a). Graphs demonstrate bone 
mineral content.
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and bisphosphonate therapy. This hypothesis is supported by the fact that also the two other reported sisters, 
who haven’t had immunosuppressive treatment, clinically improved after bisphosphonate therapy was started. 
Furthermore MMP2 has not been reported to trigger auto-inflammatory cascades, thus patients with MONA 
spectrum disorder might hardly benefit from immunosuppression33.
Besides our study there are two more reports on the use of bisphosphonates for the treatment of MONA spec-
trum disorder. Phadke et al.19 administered intravenous pamidronate in a dose of 1 mg/kg/d on three consecutive 
days at four-monthly intervals for 3 years in two siblings affected with MONA spectrum disorder. Similarly to 
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Zankl  
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8 Zankl et 
al.11
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9 Castberg  
et al.2
Ekbote  
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1 Our study
origin
3 families from Saudi 
Arabia, no MMP2 
mutation detected in 
family 2
Southern 
Italy Algeria n.i. Turkey n.i. Korea Egypt Morocco Indian 2 Italian siblings Turkey
consanguinity yes yes yes n.i. yes yes no yes yes no yes probable
Diagnosis NAO Winchester Winchester Torg MONA Torg-Winchester
Torg-
Winchester Torg-Winchester MONA Torg MONA MONA
Clinical and 
radiological 
features
family 1 family 3 family 1 family 2 patient II-1 patient II-3
osteolysis
carpal and tarsal + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +++
other bones + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++
wide metacarpals yes yes no no yes yes yes no no no no yes n.i. n.i.
osteoporosis + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +++
subcutaneous 
nodules yes yes no no yes yes yes no yes yes yes yes yes yes no
facial 
dysmorphism yes yes slightly slightly no yes no no yes yes yes yes slightly slightly yes
skin lesions/
hirsutism yes yes yes in childhood (1/2) yes yes no yes yes yes no yes yes yes yes
ocular defects no no no no no yes chronic papilledema no no no no no
bilateral 
pterygium no
iris 
coloboma
intelectual 
disability no no no no no no no no no no no no no no no
cardiac 
manifestations no no no no no BAV, TGA ASD II no no MVP
DORV, 
VSD, CoA no
AV  
block I°
early-onset 
arterial 
hypertension
VSD/ASD II
other 
manifestations/
co-morbidities
no no
colloid 
nodular 
goitre, 
DM I
no no no no no polycystic ovaries no no
premature 
thelarche no no
3-MCC-
deficiency, 
omphalocele/
VUR
age of  
diagnosis n.i. 8 m/1 y 2 y 6 m/3 y 8 m 6 m/3 m 5 y/6 y 3 y 2 y/4.5 y 4 y 5 y 3 y infancy 3 y 4 y/7 y/5 y
age at 
description n.i. 4/20 y 21 y 24 y/35 y 9 y 6 y/4 y 13 y/11 y 31 y 17 y/16 y 10 y 8 y n.i. 43 y 37 y 14 y/8 y/6 y
Mutation MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2 MMP2
family 1 family 3 2 mutations in the same patient
exon 2 5 8 8 2 8 11 4 8 n.i. 3 n.i. n.i 8 8 11
nucleotide 
change c.591G> A
c.1021C> 
A
c.1210G> 
A c.1488_1490delTGG c.302G> A c.1357delC c.1732delA
c.658+ 
2T> C
c.1217G> 
A c.540T> G
c.452G> 
A c.301C> T
c.538G> 
A
c.1228G> 
C c.1228G> C c.1699C>T
amino-acid 
change p.R101H p.Y224X p.E404K p.V400del p.R101H p.1957delC n.i. p.G406D pAsp180Glu p.W151X p.R101C p.D180N p.G410R p.G410R p.R567X
type of mutation missense nonsense missense deletion missense nonsense frameshift missense missense nonsense missense n.i. missense missense stop
protein domain prodomain
first 
fibronectin 
type-II 
domain
catalytic 
domain catalytic domain prodomain
before 
hemopexin 
domain
hemopexin 
domain
catalytic 
domain n.i. n.i. prodomain n.i
catalytic 
domaine
catalytic 
domaine
hemopexin 
domain
Table 1.  Clinical presentation and MMP2 mutations in patients with MONA spectrum disorder (formerly 
named nodulosis, arthropathy and osteolysis (NAO) syndrome, Winchester, Torg or Torg-Winchester 
syndrome) reported in the literature including our patients. Abbreviations used in the Table: ASD = atrial 
septal defect, AV block I° = first-degree atrioventricular block, BAV = bicuspid aortic valve, CoA = coarctatio of 
the aorta, DM I = diabetes mellituy type I, DORV = double outlet right ventricle, m = month, MVP = mitral valve 
prolaps, n.i. = not indicated in the manuscript, TGA = transposition of the great arteries, VSD = ventricular septal 
defect, VUR = vesicoureteral reflux, y = year.
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our study they noticed a subjective decrease in pain, tenderness and joint contractures at the wrist as well as 
increase of bone mineral density of the axial skeleton but no increase at the radius and ulna. Al-Mayouf et al.34 
treated seven children with NAO syndrome with intravenous pamidronate. The dosis was 2 mg/kg on each of 
three consecutive days every three month for one year. The patients were maintained on 800 IU/day vitamin D 
and at least 800 mg/day of elemental calcium supplement. The authors also noticed a decrease in limb and joint 
pain and improvement in functional ability although not significant. However bone mineral density had increase 
significantly in all patients at the end of treatment34.
Promising results of bisphosphonate therapy have been already reported multiple times in other inherited 
osteolysis syndromes in children, i.e. inherited multicentric osteolysis35. Three siblings were treated with intrave-
nous pamidronate at an initial dose of 0.5 mg/kg, which was increased to 1 mg/kg administered monthly for the 
next six months. Pain improved dramatically, no new fractures or focal osteolytic areas occurred. Similar to our 
patients, range of motion did not improve. Positive effects of bisphosphonates were also observed in patients with 
complex regional pain syndrome (CRPS), especially if they had osteopenic or osteoporotic changes in the affected 
limb. Amelioration of symptoms was observed both in patients who were treated orally (eg. alendronate) and 
intravenously (eg. clodronate or pamidronate)36–40. However the positive effects of bisphosphonates in CRPS are 
probably not related to their antiresorptive properties but to the fact that they might be able to modulate various 
inflammatory mediators that are up-regulated in CRPS-I40. This fact might also contribute to the positive effect of 
bisphosphonates observed in the treatment of MONA spectrum disorder.
Conclusion
From the presented data we conclude that bisphosphonates are a suitable treatment option to reduce skeletal pain 
thereby increasing quality of life in patients with MONA spectrum disorder. Early initiation of therapy, i.e. when 
first symptoms of the disease appear seems to be particularly important to achieve the most favourable outcome. 
From our experience we suggest that bisphosphonates are a treatment option for patients suffering from a MONA 
spectrum disorder. Although range of motion does not improve, bisphosphonate therapy seems to be able to 
reduce skeletal pain in these patients.
Methods
Assessment of the patients. After informed consent had been obtained from the parents we assessed 
the patients regarding the following characteristics: consanguinity, clinical symptoms at diseases on-set, age at 
on-set of symptoms and age at diagnosis, cognitive development, progression of clinical symptoms related to the 
diagnosis, molecular investigations, associated disorders as well as therapies besides bisphosphonate therapy. 
Informed consent from the parents was also obtained to publish the patient’s photographs. All investigations 
were performed according to the relevant ethical guidelines. The experimental protocols were approved by the 
Department of Pediatrics of the Medical University of Innsbruck, Austria. The trial was registered in the registry 
and results database ClinicalTrials.gov on 1st July 2016 (registration number NCT02823925).
Bisphosphonate therapy. The reported patients received intravenous bisphosphonate therapy either with 
pamidronate (1 mg/kg/d on two consecutive days every 3 months) or zoledronate (a single dose of 0.05 mg/kg/day 
every 6 month).
Evaluation of disease progression and therapeutic success. To assess both progression of MONA 
spectrum disorder and therapeutic success the patients were regularly evaluated clinically in 3 to 6 month inter-
vals. Clinical evaluation comprised an internal, neurological and orthopaedic status as well as a general assess-
ment of neurocognitive function. Additionally, need for oral analgesic therapy was documented. In irregular 
intervals, depending also on the clinical symptoms, x-rays of hands and feet were taken and a densitometry of the 
total body, lumbar spine and hip was performed.
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